Pharmaceutical company Merck is suing the Biden administration over its law empowering Medicare to negotiate for lower prices on some drugs, passed as part of last year’s Inflation Reduction Act. Among others, Merck’s highly anticipated cancer medication could be affected by the change. The White House responded to the suit Tuesday.

Press Secretary Karine Jean-Pierre: “There is nothing in the Constitution that prevents Medicare from negotiating lower drug prices. Anytime profits of the pharmaceutical industry are challenged, they make claims about it hindering their ability to innovate. Not only are these arguments untrue, but the American people do not buy them.”